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We compared the abilities of positron emission tomography and computed 
tomography todetect N2 or N3 lymph node metastases (N2 or N3) in patients 
with lung cancer. Positron emission tomography detects increased rates of 
glucose uptake, characteristic of malignant cells. Patients with peripheral 
tumors smaller than 2 cm and a normal mediastinum were ineligible. All 
patients underwent computed tomography, positron emission tomography, 
and surgical staging. The American Thoracic Society lymph node map was 
used. Computed and positron emission tomographic scans were read by 
separate radiologists blinded to surgical staging results. Lymph nodes were 
"positive" by computed tomography if larger than 1.0 cm in short-axis 
diameter. Standardized uptake values were recorded from areas on positron 
emission tomography corresponding to those from which biopsy specimens 
were taken; if greater than 4.2, they were called "positive." Seventy-five lymph 
node stations (2.8 per patient) were analyzed in 27 patients. Computed 
tomography incorrectly staged the mediastinum as positive for metastases in 
three patients and as negative for metastases in three patients. Sensitivity and 
specificity of computed tomographic scans were 67% and 83%, respectively. 
Positron emission tomography correctly staged the mediastinum in all 27 
patients. When analyzed by individual node station, there were four false 
positive and four false negative results by computed tomography (sensitivity = 
60%, specificity = 93%, positive predictive value = 60%). Positron emission 
tomography mislabeled one node station as positive (100% sensitive, 98% 
specific, positive predictive value 91%). The differences were significant when 
the data were analyzed both for individual lymph node stations (p = 0.039) and 
for patients (p = 0.031) (McNemar test). Positron emission tomography and 
computed tomography are more accurate than computed tomography alone in 
detecting mediastinal lymph node metastases from non-small-cell lung cancer. 
(J THORAC CARDIOVASC SURG 1996;111:642-8) 
C omputed tomography (CT) is commonly used for preoperative assessment of the mediastinum in 
patients with non-small-cell lung cancer (NSCLC). 1 
However, in many recent studies, the sensitivity and 
specificity of CT for detecting the presence or 
absence of mediastinal lymph node metastases in 
these patients was low (60% to 65%). 2, 3 CT detec- 
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tion of lymph node metastases in patients with 
NSCLC is based on lymph node size criteria, with 
lymph nodes greater than i cm in short-axis diame- 
ter generally considered to contain metastases. 3 
Positron emission tomography (PET) detects in- 
creased rates of glucose metabolism, characteristic 
of malignant cells, by measuring the uptake of a 
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positron-emitting lucose analog [2-18F]fluoro-2- 
deoxy-D-glucose (FDG). 4' 5 FDG-PET  can differen- 
tiate malignant from benign lung tumors 5-7 and can 
detect he presence of metastases from primary lung 
cancers to mediastinal lymph nodes 7' 8 and scalene 
lymph nodes. 9 The aims of the current study were 
(1) to confirm the ability of FDG-PET  to accurately 
predict the presence or absence of mediastinal 
lymph node metastases in patients with NSCLC, 
with histologic analysis of lymph node tissue in all 
patients used as the gold standard, (2) to develop 
semiquantitative methods (standardized uptake val- 
ues, SUVs) for analyzing the information contained 
in FDG-PET  images, and (3) to prospectively eval- 
uate the ability of FDG-PET  supplemented by CT 
to detect mediastinal ymph node metastases in 
patients with lung cancer compared with the ability 
of CT to do so. 
Patients and methods 
We prospectively compared the ability of FDG-PET 
and of CT to detect regional lymph node metastases in 27 
patients with known or suspected NSCLC. Patients were 
excluded from analysis (1) if they were not appropriate 
candidates for mediastinoscopy or thoracotomy or (2) if 
the only abnormality on chest CT scan consisted of a 
solitary pulmonary nodule 2 cm in diameter or less 
without CT evidence of mediastinal lymph node enlarge- 
ment. All patients who agreed to participate in the trial 
gave written informed consent. The protocol was ap- 
proved by the institutional review boards at the partici- 
pating institutions. 
CT. The CT scans were obtained on a General Electric 
(Brookfield, Wis.) 9800-Hilite-HTD scanner. Routine im- 
ages were obtained to the level of the adrenal glands, with 
10 mm collimation at 10 mm table increments, using 120 
kV, 120 mA, 2-second scans reconstructed with standard 
algorithms. Isovue 300 (iopamidol 61%) was used for 
intravenous contrast enhancement and was infused at a 
rate of 0.5 ml/min for 60 seconds, then increased to 1.5 
ml/min to a complete infusion of 140 ml for the total 
volume. CT was performed before PET in all patients. 
PET. A Siemens/CTi ECAT 931 positron emission 
tomograph (CTI, Knoxville, Tenn.) with a 12 cm axial field 
of view was used for all patients. FDG was synthesized 
according to standard methods with the Siemens/CTI 
chemical processing control unit and radioisotope delivery 
system. Quality control tests were performed on-site. The 
purity of FDG exceeded 95% for all doses. The total FDG 
dose ranged from 9.5 to 11 mCi. 
Images were acquired by means of the following proto- 
col. Patients took nothing orally for at least 4 hours. 
Informed consent was obtained. A rectilinear transmis- 
sion scan was acquired to aid in positioning the patient 
after inspection of a plain Chest radiograph or CT scan to 
determine the location of the lung mass. A 0.5 ml sample 
of blood was drawn for determination of the baseline 
blood glucose level (no manipulation of the blood glucose 
level was done) and the data were recorded. The FDG 
was administered intravenously. After a 60-minute uptake 
period, the patient was positioned in the scanner once 
again. An emission scan was acquired at 20 minutes for 
each bed position (an image of the thorax requires two 
bed positions on average) for a total of 40 minutes. Image 
reconstruction done by measured attenuation correction 
was performed by means of a Hann filter with 0.5-pixel 
cutoff. The transaxial images were reconstructed into 
sagittal and coronal planes. 
Interpretation of studies. CT scans were interpreted by 
one radiologist (J.T:) who had no knowledge of the 
identity of the patient, the findings of surgical staging 
procedures, or the results of other imaging studies. Me- 
diastinal lymph nodes were localized according to the 
lymph node map proposed by the American Thoracic 
Society] ° Regional ymph nodes were considered to con- 
tain metastatic tumor if they were greater than 1.0 cm in 
short-axis diameter. The size and location of the primary 
tumor, as well as the presence of postobstructive atelec- 
tasis, mediastinal invasion, chest wall invasion, pleural 
effusion, or other pertinent findings, were recorded on 
standardized data sheets. Any abnormalities of the bones, 
liver, or adrenal glands were also recorded. 
FDG-PET scans were interpreted by one nuclear med- 
icine physician (EGO. The corresponding CT scan was 
available for review by this physician when the PET was 
interpreted. The nuclear medicine physician did not know 
the identity of the patient, the findings of surgical staging, 
or the results of imaging studies other than CT. PET 
images were displayed in Imagetool on a Sun microsys- 
terns SparcStation 1+ using axial planes (Sun Microsys- 
terns, Mountain View, Calif.). Co-registration of CT and 
PET images was not performed. CT was used to define the 
location of specific areas of increased FDG uptake seen 
on PET, which were thought to represent either the 
primary malignant umor or regional metastases. These 
areas were generally characterized asbeing focal, spheri- 
cal regions where the FDG uptake was increased over that 
of the immediately adjacent tissue. Streaky or linear areas, 
focal areas with FDG uptake similar to that of the 
surrounding tissue, and areas near the base of the heart 
(where normally high rates of glucose uptake by atrial 
tissue can be measured) were not generally considered to 
represent malignant issue. As used throughout this re- 
port, the phrase mediastinal FDG uptake refers to FDG 
uptake by noncardiac tissue. Symmetrical areas of FDG 
uptake near areas of skeletal muscle or the thyroid gland 
were not indicative of malignant tissue. 
A semiquantitative analysis was performed. The 
amount of FDG uptake in a given region was converted 
into a unitless number, the SUV. The SUV normalizes the 
amount of FDG uptake for the body weight of the patient 
and the specific dose of FDG injected. The maximum 
radionuclide concentration for a given region (maximum 
FDG uptake expressed as microcuries per milliliter 
[/xCi/ml]) wa s identified. That number was then converted 
into the SUV for that region by the formula~ SUV = 
(txCi/ml)" (kg/mCi). No recovery coefficient or glucose 
correction was applied. 
Because the "background," or normal, amount of glu- 
cose uptake varies for different regions in the chest, 
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Table I. Mediastinal lymph node status by CT, 
analyzed according to patient 
CT 
Present Absent 
Histology (+) 6 3 
Histology (-) 3 15 
9 18 
Table I I I .  Mediastinal lymph node status by PET, 
analyzed according to patient 
PET 
Present Absent 
Histology (+) 9 0 
Histology (-) 0 18 
9 18 
Table II. Mediastinal lymph node status by CT, 
analyzed by lymph node level 
CT 
Present Absent 
Histology (+) 6 4 
Histology ( ) 4 61 
10 65 
different hreshold values of SUV were used to diagnose a
primary malignant lung tumor as opposed to a mediastinal 
lymph node metastasis. Because the background uptake 
of glucose per unit volume in the normal ung is low, we 
have found that a relatively low radionuclide concentra- 
tion, corresponding to an SUV of 2.0, differentiates 
malignant from benign lung masses with a high degree of 
accuracy. We 7 therefore consider masses in the lung with 
an SUV greater than 2.0 to be malignant. The background 
rate of glucose uptake per unit volume in the mediastinum 
is normally greater than that in the lung. On the basis of 
previous, unpublished, data, we have chosen an SUV of 
4.2 as the threshold value for differentiating benign from 
malignant tissue in the mediastinum. Therefore, areas of 
FDG uptake in the mediastinum with an SUV greater 
than 4.2 (excluding the heart) were Considered tO have a 
rate of glucose metabolism consistent with that of malig- 
nant tissue. 
The location of specific areas of increased uptake in the 
mediastinum was assigned by the nuclear medicine physi- 
cian according to the American Thoracic Society lymph 
node mapping system. If no specific areas of increased 
uptake in the mediastinum or supraclavicular regions 
were identified, the nuclear medicine physician identified 
the pixel within the mediastinum (noncardiac portion) 
with the greatest concentration fFDG. The SUV for that 
region was calculated and represented the maximum 
amount of uptake for the entire mediastinum; for exam- 
ple, if that SUV was smaller than 4.2, then the mediasti- 
num was considered to be free of lymph node metastases. 
Surgical confirmation. Proof of the presence or ab- 
sence of malignancy in primary tumors was obtained for 
all patients by one or more of the following techniques: 
bronchoscopy, transthoracic needle biopsy, thoracoscopy, 
and thoracotomy. Confirmation of the presence or ab- 
sence of mediastinal lymph node metastases was obtained 
in all patients by scalene node biopsy, mediastinoscopy, or 
thoracotomy. All accessible mediastinal lymph nodes were 
either removed or sampled. The location of mediastinal 
lymph nodes was determined by the thoracic surgeon 
during the operation by means of the American Thoracic 
Society lymph node map. Biopsy specimens of bulky nodal 
metastases were assigned to the closest corresponding 
lymph node level. Lymph nodes from level 10R were 
considered mediastinal lymph nodes. Both the PET and 
CT images were available to the surgeon during the 
operation. 
Data analysis. The sensitivity, specificity, positive pre- 
dictive value, negative predictive value, and accuracy of 
CT alone and of FDG-PET as an adjunct o CT for the 
assessment of mediastinal lymph node metastases were 
determined. Predictions of lymph node status by either 
method were analyzed by patient, that is, whether a test 
determined the correct mediastinal node status in a given 
patient. Mediastinal lymph node assessment byeach test was 
also analyzed by lymph node level. The relative accuracy of 
CT alone and of FDG-PET as an adjunct to CT was 
compared by applying the McNemar test for correlated 
proportions (exact est, one-sided).11 Ap value of 0.05 or less 
indicated astatistically significant difference between the two 
methods. 
Results 
Patient population. A total of 27 patients under- 
went both CT and FDG-PET.  The group included 5 
women and 22 men, with an average age of 64.4 
years (range 40 to 85 years). All patients underwent 
CT followed by FDG-PET.  CT and FDG-PET  were 
performed within 9.2 _+ 1.6 days (mean _+ standard 
error of the mean) of each other (range up to 30 
days). Three patients underwent both studies on the 
same day. A total of 19 patients underwent both 
studies within 8 days or less. All patients had 
NSCLC. There were 10 adenocarcinomas (including 
1 bronchioloalveolar carcinoma), 13 squamous cell 
carcinomas, 4 large-cell carcinomas, and 1 NSCLC. 
The primary cancers ranged in size (greatest dimen- 
sion) from 1.2 to 10.0 cm, with an average size of 
3.8 _+ 0.4 cm (mean +_ standard error of the mean). 
Surgical staging. The study participants under- 
went the following surgical staging procedures: me- 
diastinoscopy (n = 9), thoracotomy (n = 19), tho- 
racoscopy (n = 1), and scalene lymph node biopsy 
(n = 2). A total of 75 (2.8 per patient) mediastinal 
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Table IV. Mediastinal lymph node status by PET, 
analyzed by l mph node level 
PET  
Present Absent 
Histology (+) 10 0 
Histology (-)  1 64 
11 64 
(N2 or N3) lymph node stations were sampled. 
Cancer cells were present in 10 of 75 lymph node 
stations (13.3%) and nine of 27 patients (33.3%) 
according to routine light microscopic analysis. 
The mean size (+ standard error of the mean) of 
primary tumors without histologically proved medi- 
astinal ymph node metastases was 4.10 _+ 0.58 cm 
compared with 3.22 _+ 1.66 cm for primary tumors 
associated with histologically proved mediastinal 
lymph node metastases (p = 0.126, unpaired t test). 
The percentage of centrally located primary tumors 
was higher in the group with histologically proved 
mediastinal metastases (5/9, 56%) than in the group 
without histologically proved mediastinal metastases 
(4/18, 22%). 
CT. CT identified the primary tumors in all in- 
stances. Pleural effusions were present in three pa- 
tients. In two of three instances, these were small 
effusions contralateral to the tumor. Thoracentesis was 
performed in all cases. The pleural fluid was negative 
for malignant cells by cytologic analysis. Atelectasis 
extending to the hilum was present in nine of the 27 
patients (in 5/9 with mediastinal metastases and 4/18 
without mediastinal lymph node metastases). The pri- 
mary tumor was described as abutting the visceral 
pleura in 10 of the 27 patients. No patient had chest 
wall invasion described on CT, and chest wall invasion 
was not found during the surgical staging procedures. 
Mediastinal invasion was described in one patient, who 
had a hard, fixed mass in the same location at the time 
of mediastinoscopy. No evidence of bone, liver, or 
adrenal metastases was noted by CT in any patient. 
The data were analyzed for patients and by indi- 
vidual lymph node levels. CT incorrectly staged the 
mediastinum as "positive" or "negative" for lymph 
node metastases in three patients each. CT correctly 
predicted the presence or absence of lymph node 
metastases in 21 of the 27 patients. CT sensitivity 
and positive predictive value were 67% (6/9), 
whereas specificity and negative predictive value 
were 83% (15/18) (Table I). The accuracy of CT was 
therefore 78% (21/27). None of the patients in 
Fig. 1. CT showing enlarged right paratracheal lymph node 
(white arrow) in a 65-year-old patient with a primary lung 
cancer of the right middle obe. Other CT images howed 
enlarged lymph nodes along the entire right side of the 
trachea (extranodal r bulky disease, positive CT results). 
whom CT falsely indicated the presence of medias- 
tinal metastases had postobstructive atelectasis or 
atelectasis extending to the hilum on CT. 
When analyzed by individual ymph node sta- 
tion, CT incorrectly identified four stations as 
positive and four stations as negative. CT cor- 
rectly identified the presence or absence of lymph 
node metastases in the other 67 lymph node 
stations that were sampled. The sensitivity and 
positive predictive value of CT were 60% (6/10) 
and the specificity and negative predictive value 
were 94% (61/65) (Table II). The accuracy of CT 
in this analysis was therefore 89% (67/75). The 
specificity was high because of the many true 
negative mediastinal lymph node levels that were 
present in the study population. 
PET. FDG-PET correctly identified all primary tu- 
mors as malignant. The SUV (mean _+ standard error 
of the mean) for the 27 primary lung cancers was 
11.82 _+ 1.26. The SUV for primary tumors associated 
with mediastinal lymph node metastases was 13.94 _+ 
2.17 compared with 11.19 _+ 1.5 for primary tumors 
not associated with mediastinal lymph node metasta- 
ses (p = 0.44, unpaired t test). Data regarding medi- 
astinal lymph node metastases were analyzed both for 
the mediastinum asa whole (analyzed per patient) and 
for each lymph node level that was sampled for biopsy. 
PET correctly predicted the presence or absence of 
lymph node metastases in the mediastinum in all 
patients (Table III). In this series of patients, the 
sensitivity and specificity of FDG-PET for staging the 
mediastinum was 100%. FDG-PET was less accurate 
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Fig. 2. Coronal FDG-PET image from the same patient showing uptake (SUV - 9.96) in the right middle 
lobe (lower arrow) and uptake consistent with metastatic cancer (SUV = 4.59) in the right paratracheal 
lymph node chain (upper arrow). The right paratracheal lymph nodes contained cancer at mediastinoscopy 
(both PET and CT had true positive results). Uptake at the lower left side of the patient is from the heart. 
Fig. 3. CT of the mediastinum from a 68-year-old man 
with adenocarcinoma of the right upper lobe showing an 
enlarged pretracheal lymph node (white arrow). FDG- 
PET measured a maximum SUV of 3.32 for the medias- 
tinum (negative FDG-PET result). This lymph node and 
others removed at thoracotomy were negative for cancer 
(CT, false positive result; FDG-PET, true negative result). 
at identifying metastases and localizing them to spe- 
cific lymph node levels (Table IV). FDG-PET misla- 
beled one histologically negative lymph node level as 
positive in a patient who had other mediastinal metas- 
tases present in other lymph node levels that were 
correctly identified by FDG-PET. The stage of disease 
in this patient (according to the criteria of the Amer- 
ican Joint Commission on Lung Cancer) was not 
changed by the false positive designation. When ana- 
lyzed on the basis of lymph node level, the sensitivity of 
FDG-PET was 100% (10/10), the positive predictive 
value was 91% (10/11), the specificity was 98% (64/65), 
and the negative predictive value was 100% (64/64). 
The accuracy of FDG-PET for detecting metastases in 
indMdual lymph node levels was 99% (74/75). 
Comparison of CT and PET. The McNemar test 
for correlated proportions (exact test version) was 
used to compare the ability of FDG-PET  and CT 
to identify the presence or absence of lymph node 
metastases in patients with NSCLC. A one-sided 
test was performed. When the data were analyzed 
for patients, there were six discrepancies between 
CT and FDG-PET  over the presence or absence 
of lymph nodes in the mediastinum as a whole. In 
each of these instances, FDG-PET  was correct 
and CT was wrong, as compared with the histo- 
logic results. The McNemar test indicated that the 
difference was significant, with a p value of 0.031. 
When the analysis was repeated for individual 
lymph node levels, there were nine differences 
between CT and FDG-PET,  and eight of the nine 
favored FDG-PET.  In this case, the difference was 
also significant, with a p value of 0.039. We 
therefore conclude that FDG-PET  is more accu- 
rate than CT in predicting the presence or ab- 
sence of mediastinal lymph node metastases in 
patients with NSCLC (Figs. 1 to 3). 
Discussion 
The clinical use of PET in patients with cancer is 
based on an observation by Warburg 4 that the 
malignant ransformation of liver cells was accom- 
panied by a decreased ability to make energy aero- 
bically. Because anaerobic glycolysis produces much 
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less energy from glucose, high rates of glucose 
uptake are necessary for the survival of malignant 
cells. PET can estimate the rate of glucose metab- 
olism in tissue by measuring the uptake of a glucose 
analog, FDG, by the tissue over time. FDG is a 
positron-emitting radionuclide that can be detected 
by PET. Under steady state conditions, FDG is 
taken up by cells in a competitive fashion with other 
hexoses. Once inside the cell, FDG is phosphory- 
lated. It cannot be metabolized further and it cannot 
diffuse out of the cell. The amount that accumulates 
in tissue over a certain period provides an estimate 
of the rate of glucose (hexose) uptake by that tissue. 
The application of FDG-PET to oncology is based 
on its ability to detect different rates of glucose 
metabolism in benign and malignant tissues. 5
Many studies have documented the ability of FDG- 
PET to differentiate benign from malignant lung 
masses.5-7, 12-14 We 7, 9 and others 8 have extended these 
observations to include the detection of mediastinal 
and scalene lymph node metastases in normal-sized 
lymph nodes by FDG-PET. Chin and associates is have 
documented the ability of FDG-PET to detect small 
loci of lung cancer in single lymph nodes. The results 
of the current study support these observations. FDG- 
PET was able to accurately identify lymph node me- 
tastases with a low false positive rate. FDG uptake by 
inflammatory cells can produce false positive readings 
in patients with pneumonias or active fungal infec- 
tions. 14 Despite the presence in this study of several 
patients with postobstructive changes and atelectasis 
extending to the hilum on CT, FDG-PET was accurate 
at staging the mediastinum in each. Furthermore, 
FDG-PET was able to detect scalene lymph node 
metastases in two patients with metastases to scalene 
lymph nodes that were not detected either clinically or 
by CT. 
We used a semiquantitative approach to analyze 
the images generated by the FDG-PET study. We 
believe the use of semiquantitative m thods prom- 
ises to improve the interpretation of FDG-PET 
images. A threshold SUV of 4.2 accurately differen- 
tiated benign from malignant mediastinal lymph 
nodes in the current study. More data are required 
to determine the optimal threshold value for the 
evaluation of the mediastinum. A quantitative ap- 
proach will eventually allow investigators toretrieve 
more information from the images than can be 
retrieved through visual inspection alone. 
FDG-PET supplemented by CT was more accurate 
than CT alone at predicting the presence or absence of 
lymph node metastases in patients with NSCLC. CT 
provides anatomic detail that cannot be provided by 
PET. However, CT criteria for detecting lymph node 
metastases rely on lymph node size. Lymph nodes that 
contain cancer are often not enlarged, and enlarged 
lymph nodes often do not contain cancer. Therefore, 
we believe that the two studies are best used concur- 
rently. Wahl and his group sfound that he information 
provided by computer-generated "fusion" images of 
standard CT and PET images was similar to that 
obtained from analysis of the separate images. 
The current study provides information that may 
improve the staging and selection for treatment of 
patients with NSCLC. The most appropriate use of 
PET technology in the treatment of patients with 
malignant disease of the thorax will be determined 
through further esearch. We found that FDG-PET 
supplemented by CT is more accurate than CT 
alone for staging the mediastinum in patients with 
lung cancer. We and others are conducting studies 
designed to investigate the ability of FDG-PET to 
detect clinically unsuspected distant metastases, to
detect recurrent cancer, and to assess the response 
to treatment of malignant umors of the thorax. 
These data could be used to compare clinical algo- 
rithms incorporating FDG-PET with current reat- 
ment approaches through the use of decision anal- 
ysis. Cost can be included in this type of analysis. By 
using these methods, we hope to determine the 
appropriate, cost-effective use of FDG-PET in the 
diagnosis and treatment of malignant umors of 
the thorax. 
REFERENCES 
1. Little AG, Stitik FP. Clinical staging of patients with non- 
small cell lung cancer. Chest 1990;97:1431-8. 
2. Webb WR, Gatsonis C, Zerhouni EA, et al. CT and MR 
imaging in staging non-small cell bronchogenic carcinoma: 
report of the Radiologic Diagnostic Oncology Group. Radi- 
ology 1991;178:705-13. 
3. McLoud TC, Bourgouin PM, Greenberg RW, et al. Bron- 
chogenic arcinoma: analysis of staging in the mediastinum 
with CT by correlative lymph node mapping and sampling. 
Radiology 1992;182:319-23. 
4. Warburg O. On the origin of cancer cells. Science 1956;123: 
309-14. 
5. Nolop KB, Rhodes CG, Brudin LH, et al. Glucose utilization 
in vivo by human pulmonary neoplasms. Cancer 1987;60: 
2682-9. 
6. Patz EF, Lowe VL, Hoffman JM, et al. Focal pulmonary 
abnormalities: evaluation with F-18 fluorodeoxyglucose PET 
scanning. Radiology 1993; 188:487-90. 
7. Scott WJ, Schwabe JL, Gupta NC, et al. Positron emission 
tomography of lung tumors and mediastinal lymph nodes 
using [18F]fluorodeoxyglucose. Ann Thorac Surg 1994;58: 
698-703. 
8. Wahl RL, Quint LE, Greenough RL, Meyer CR, White RI, 
648 Scott et al. 
The Journal of Thoracic and 
Cardiovascular Surgery 
March 1996 
Orringer MB. Staging of mediastinal non-small cell lung 
cancer with FDG PET, CT, and fusion images: preliminary 
prospective evaluation. Radiology 1994;191:371-7. 
9. Scott WJ, Gobar LS, Hauser LG, Sunderland JJ, Dewan NA, 
Sugimoto JT. Detection of scalene lymph node metastases 
from lung cancer: positron emission tomography. Chest 
1995;107:1174-6. 
10. Tisi GM, Friedman PJ, Peters RM, et al. Clinical staging of 
primary lung cancer. American Thoracic Society node mapping 
scheme. Am Rev Respir Dis 1983;127:344-7. 
11. Rosner B. Fundamentals of biostatistics. 3rd ed. Boston: 
PWS-Kent Publishing Company, 1990:345-8. 
12. Kubota K, Matsuzawa T, Ito M, et al. Differential diagnosis of
lung tumor with positron emission tomography: a prospective 
study. J Nucl Med 1990;31:1927-32. 
13. Knopp MV, Strauss LG, Haberdorn U, et al. Positron 
emission tomography (PET) with F-18-fluorodeoxyglucose in 
the imaging and staging of bronchogenic carcinoma. Eur J 
Nucl Med 1991;32:623-48. 
14. Dewan NA, Gupta NC, Redepenning LS, Phalen JJ, Frick 
MP. Diagnostic e~cacy of PET-FDG imaging in solitary 
pulmonary nodules: potential role in evaluation and manage- 
ment. Chest 1993;104:997-1002. 
15. Chin R, Ward R, Cappellari JC, Keyes J, Haponik EF. 
Mediastinal node (N2) involvement by PET-FDG scanning 
in non- small cell lung carcinoma (NSCLC): pathologic 
correlation. Chest 1994;106:89S. 
Discuss ion 
Dr. Valerie W. Rusch (New York, N.Y.). PET is a 
promising new imaging modality in patients with cancer 
because it can potentially distinguish between benign and 
malignant tissues by exploiting a known biochemical dif- 
ference, namely, that malignant cells are characterized 
by increased glucose metabolism and protein synthesis. 
Dr. Scott and his colleagues have an established interest in 
studying the role of PET scanning in patients with lung 
cancer. This study extends their prior work, which showed 
that PET has about an 80% specificity in identifying 
malignant lung tumors. 
This study is well designed and suggests that PET is 
more accurate in detecting mediastinal lymph nodal me- 
tastases than is CT. However, it emphasizes that PET, like 
monoclonal ntibody imaging, may not be useful in assess- 
ing either small primary tumors or normal-sized lymph 
nodes that are involved by tumor. The study also empha- 
sizes that the spatial resolution of PET is limited. 
On the basis of your experience, Dr. Scott, could you 
comment on several points pertaining to the clinical useful- 
ness of PET? Specifically, what was the sensitivity, specificity, 
and accuracy of PET in assessing lymph nodes that were 1 
cm or less in size? Have you begun to assess the role of 
CT/PET fusion imaging (as has been done in monoclonal 
antibody imaging) to try to improve the spatial resolution of 
PET? Given the limitations of PET that you have outlined, 
do you foresee situations in which it would replace medias- 
tinoscopy or mediastinal lymph node dissection i  the stag- 
ing of disease in patients with previously untreated lung 
cancer? I find it hard understand how these low-risk surgical 
procedures, which are the gold standard of lung cancer 
staging, will be supplanted by noninvasive imaging modali- 
ties, including PET scanning. What is the current cost of a 
PET scan and of the equipment? Could you comment on the 
relative value of FDG versus methionine scanning? Finally, 
do you foresee that the most durable application of this new 
modality may be to detect extrathoracic disease rather than 
mediastinal nodal metastases or to evaluate patients for 
recurrent or persistent tumor after nonsurgical treatment? 
Dr. Scott. The spatial resolution of PET scan is limited, 
and that is why we have tried to use CT scan along with it. 
In our study, PET correctly identified four lymph node 
levels as positive for metastatic disease in four instances in
which CT criteria falsely classified them as negative (<1 
cm). There were no lymph nodes I cm or smaller classified 
as falsely positive by PET. At the meeting of the American 
College of Chest Physicians, Dr. Chin, from North Caro- 
lina, reported results of several patients who had lymph 
nodes less than 1 cm in size, all of whom had metastases 
detected by PET scan. I think PET can work very well. 
We do not use CT and PET fusion images. Dr. Wohl, 
from Michigan, did not find much difference between using 
CT as a supplement to PET, as we did, and actually trying to 
fuse the scans into a computer-generated autometabolic 
image. 
I would foresee this modality possibly replacing medi- 
astinoscopy in patients in whom the primary tumor is 
known to be a cancer and in whom the study shows that 
there is no uptake in the mediastinum. I think PET is very 
reliable in that particular instance. 
The PET center at Creighton University costs appro~d- 
mately $2 million. The current cost of PET scans is decreas- 
ing all the time. The cost of PET in our study was $900. 
I have not used methionine as a radionuclide. It must be 
generated on-site because it decays rapidly. It is therefore 
less practical than FDG. Many people are interested in 
detecting cxtrathoracic disease. Those studies are difficult 
inasmuch as brain metastases cannot be detected very well 
with this method because of the uptake of FDG by normal 
brain tissue. 
Finally, I think there is a great problem with evaluating 
recurrent and persistent disease, because inflammatory 
tissue also takes up glucose. Patients who have radiation 
treatment and radiation ecrosis can have FDG uptake. It 
is difficult to know whether that represents necrosis or 
recurrent or persistent tumor. 
Dr. William H. Warren (Chicago, Ill.). At Presbyterian- 
St. Luke's Hospital we also have experience with the PET 
scan. We have studied 24 cases and obtained a false 
negative result in one. That case, not surprisingly, turned 
out to be a bronchial carcinoid. 
I have one comment regarding your conclusion that the 
PET scan may supplement the CT scan. In this day of cost 
containment, given your results and the results of others, 
I believe PET scans may be more valuable than CT scans 
and become the study of choice for staging lung cancer. 
We have had some difficulty in interpreting the subcari- 
nal nodes because of the uptake in the heart. Have you 
had this experience and can you give us any help? 
Dr. Scott. It is difficult o detect some of the lymph node 
tissues and tissues in the area of the heart. Our nuclear 
medicine physician looks for very round areas. We think that 
illustrates the value of semiquantitative analysis: If we can 
locate an area like that and the SUV is greater than 4.2, we 
have had good success in detecting those abnormalities. 
